贝伐珠单抗联合FOLFIRI方案治疗氟尿嘧啶耐药的晚期结直肠癌患者的疗效  

Efficacy of Bevacizumab Combined with FOLFIRI Regimen in the Treatment of Fluorouracil-Resistant Advanced Colorectal Cancer

作　　者：孙振敏 李婷 SUN Zhenmin;LI Ting(Department of Oncology,Changzhou Jiuzhou Jindongfang Hospital,Changzhou Jiangsu 213100)

机构地区：[1]常州九洲金东方医院肿瘤科,江苏常州213100

出　　处：《医学临床研究》2025年第2期265-267,271,共4页Journal of Clinical Research

摘　　要：【目的】探讨贝伐珠单抗联合FOLFIRI方案治疗氟尿嘧啶(FU)耐药的晚期结直肠癌患者的临床疗效。【方法】89例对FU耐药的晚期结直肠癌患者,随机分为对照组(44例,采用FOLFIRI方案治疗)和观察组(45例,采用贝伐珠单抗联合FOLFIRI方案治疗)。比较两组患者的近期及远期疗效,治疗前后肿瘤标志物水平和毒副反应发生情况。【结果】观察组近期总有效率高于对照组(P<0.05)。治疗后,两组血清糖链抗原19-9(CA19-9)、糖链抗原242(CA242)、癌胚抗原(CEA)、表皮生长因子受体(EGFR)水平均低于治疗前(P<0.05),且观察组低于对照组(P<0.05)。截至随访日期,对照组患者中位生存时间(OS)为12.0个月,观察组OS为17.0个月;两组Kaplan-Meier曲线比较,差异有统计学意义(Log-rankχ^(2)=5.624,P=0.018)。两组患者各项毒副反应发生率比较,差异均无统计学意义(P>0.05)。【结论】贝伐珠单抗联合FOLFIRI方案治疗可提升FU耐药晚期结直肠癌患者的近远期疗效,降低肿瘤标志物水平,且安全可靠。【Objective】To investigate the clinical efficacy of bevacizumab combined with the FOLFIRI regimen in treating fluorouracil(FU)-resistant advanced colorectal cancer(CRC)patients.【Methods】A total of 89 FU-resistant advanced colorectal cancer patients were randomly divided into two groups:the control group(44 patients,treated with the FOLFIRI regimen)and the observation group(45 patients,treated with bevacizumab combined with FOLFIRI regimen).The short-term and long-term efficacy,changes in tumor marker levels before and after treatment,and adverse reactions were compared between the two groups.【Results】The short-term overall response rate was significantly higher in the observation group than in the control group(P<0.05).After treatment,serum levels of carbohydrate antigen 19-9(CA19-9),carbohydrate antigen 242(CA242),carcinoembryonic antigen(CEA),and epidermal growth factor receptor(EGFR)were significantly lower than before treatment(P<0.05)in both groups,and the observation group had lower levels compared to the control group(P<0.05).At the end of the follow-up period,the median overall survival(OS)of the control group was 12.0 months,while the OS of the observation group was 17.0 months;the Kaplan-Meier curve comparison between the two groups showed a significant statistical difference(Log-rankχ^(2)=5.624,P=0.018).There were no significant differences in the incidence of adverse reactions between the two groups(P>0.05).【Conclusion】Bevacizumab combined with FOLFIRI regimen treatment improves both short-and long-term efficacy in FU-resistant advanced colorectal cancer patients,reduces tumor marker levels,and it is safe and reliable.

关 键 词：结直肠肿瘤 贝伐珠单抗 氟尿嘧啶 治疗结果 

分 类 号：R735.35[医药卫生—肿瘤]